Therefore, human anti-CLPTM1L mAbs could re-sensitize to platinum-resistant ovarian cancer cells achieved in orthotopic isografts and patient-derived cisplatin-resistant xenografts models48. Here, CLPTM1L is linked to ovarian carcinoma.